Antibiotics for Infectious Disease: 21.1% of denials overturned
In 90 California IMR decisions from 2001 to 2025, reviewers overturned 19 (21.1%). In the last five years: 66.7% of 12. 60 were medical-necessity disputes, 30 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 1 | 100.0% |
| 2022 | 6 | 66.7% |
| 2023 | 3 | 33.3% |
| 2025 | 2 | 100.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 19 | 26.3% | 21.1% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 11 | 0.0% | 21.1% |
| Experimental or investigationalThe findings discuss whether the treatment is experimental. | 9 | 0.0% | 21.1% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 7 | 42.9% | 21.1% |
| Step therapy or fail-firstThe findings mention a fail-first requirement. | 6 | 16.7% | 21.1% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 4 | 50.0% | 21.1% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Talicia. Per the medical records, the patient has attempted and failed multiple therapeutic regimens for the treatment of Helicobacter pylori and biopsies show the presence gastric intestinal metaplasia, a precancerous condition. The American College of Gastroenterology (ACG) guidelines for the management of …”
“Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement for Xifaxan tablets. Findings: A systematic review including multiple studies concluded that Xifaxan is effective in the management of recurrent Clostridium difficile infections. In this case, the patient experienced recurrent Clostridium difficile colitis despite compliance with the recommended treatment. The literature supports the use of Xifaxan in such cases. All …”
“The physician reviewer found that The patient has requested authorization and coverage for Zyvox (linezolid) 600 mg tablets taken as one tablet by mouth twice daily for 30 days. On review of the available medical records, this patient was found to have a bacterial infection in an eye as well as abscesses of the mediastinum and brain. Testing revealed the …”
And one the reviewer upheld
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for vancomycin HCL. Researchers explain, “Clostridioides difficile diagnosis is based on clinical presentation and laboratory tests confirming the presence of toxigenic strain or toxins in stools.” Researchers note, “As detection of Clostridioides difficile in clinical specimens does not always equate with disease, the diagnosis of …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Antibiotics denials for Infectious Disease overturned?
In 90 California IMR decisions from 2001 to 2025, reviewers overturned 19 (21.1%). In the last five years: 66.7% of 12. 60 were medical-necessity disputes, 30 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.